公开(公告)号：US12018021B2

公开(公告)日：2024-06-25

申请号：US16973701

申请日：2019-06-20

Applicant: UCB Biopharma SRL

Inventor： Pfrafulkumar Tulshibhai Chovatia ,  Rickki Lee Connelly ,  Richard Jeremy Franklin ,  Gregory William Haslett ,  Alistair James Henry ,  James Madden ,  Judi Charlotte Neuss ,  Timothy John Norman ,  Oliver Philps ,  William Ross Pitt ,  Konstantinos Rampalakos ,  Matthew Duncan Selby ,  Selvaratnam Suganthan ,  Giancarlo Trani ,  Zhaoning Zhu

IPC: C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

CPC classification number: C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

公开(公告)号：US11674967B2

公开(公告)日：2023-06-13

申请号：US17013326

申请日：2020-09-04

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Boris Kroeplien ,  Stephen Edward Rapecki ,  Timothy John Norman ,  Graham John Warrellow ,  Tracy Lynn Arakaki ,  Alex Buntin Burgin ,  William Ross Pitt ,  Mark Daniel Calmiano ,  David Andreas Schubert ,  Daniel John Lightwood ,  Rebecca Jayne Munro

IPC: G01N33/68 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/705 ,  C07K16/24 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

CPC classification number: G01N33/6845 ,  A61K47/6425 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  G01N33/6854 ,  G01N33/6863 ,  C07K2317/55 ,  C07K2317/92 ,  G01N2333/525 ,  G01N2500/02

Abstract: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

公开(公告)号：US20220332709A1

公开(公告)日：2022-10-20

申请号：US16973701

申请日：2019-06-20

Applicant: UCB Biopharma SRL

Inventor： Pfrafulkumar Tulshibhai Chovatia ,  Rickki Lee Connelly ,  Richard Jeremy Franklin ,  Gregory William Haslett ,  Alistair James Henry ,  James Madden ,  Judi Charlotte Neuss ,  Timothy John Norman ,  Oliver Philps ,  William Ross Pitt ,  Konstantinos Rampalakos ,  Matthew Duncan Selby ,  Suganthan Selvaratnam ,  Giancarlo Trani ,  Zhaoning Zhu

IPC: C07D409/14 ,  C07D495/04 ,  C07D333/78 ,  C07D333/50 ,  C07D409/12 ,  C07D413/12 ,  C07D487/04 ,  C07D417/12 ,  C07D498/10 ,  C07D409/04 ,  C07D413/04 ,  C07D409/06 ,  C07D495/10

Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.